For super-resolution microscopes, AI helps by restoring images from even noisy, low-fluorescence data. That capability helps ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

While House, Senate thwarted 40% cut to agency’s budget, about half of the largest recipients of agency grants saw cuts year-over-year.

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

The Center supports clients across the development and manufacturing of biologics, RNA therapeutics, vaccines, and cell and gene therapies.

NeuMap, the first single‑cell atlas of neutrophils, reveals conserved functional hubs across health, infection, and cancer, reshaping immunity.

While there are several bacteria and viruses causing pneumonia, the research team looked specifically at Streptococcus pneumoniae.

EMMI leverages “the largest global database of binding data” to generate small molecule drugs in new chemical space to tackle hard targets.

In the 1980s, the human immunodeficiency virus (HIV) was a global scourge, decimating communities. When it was identified in the blood products supply chain, people were terrified.

With the advent of AI-powered protein design tools, protein-based therapeutics may no longer be constrained by the limits imposed by natural selection.

Industrialized, small batch, and individual RNA therapeutics become practical with “in-a-box” manufacturing technology.

Xmoor expects to gain from direct collaboration with UCL’s translational researchers, enabling it to take part in technological innovation.